AbCellera Biologics Inc. Preferred Stock Dividends, Income Statement Impact
AbCellera Biologics Inc. (ABCL) reported Preferred Stock Dividends, Income Statement Impact of $33.82 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-21.
Discontinued › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2023-02-21
- AbCellera Biologics Inc. preferred stock dividends, income statement impact for the quarter ending 2020-12-31 was $33.26M.
- AbCellera Biologics Inc. preferred stock dividends, income statement impact for the quarter ending 2020-09-30 was -$646.00K.
- AbCellera Biologics Inc. preferred stock dividends, income statement impact for the quarter ending 2020-06-30 was $2.33M.
- AbCellera Biologics Inc. preferred stock dividends, income statement impact for fiscal 2020 was $33.82M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2020-12-31 | $33.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $32.61M derived: sum of 2 quarters · filed 2023-02-21 | $34.94M derived: sum of 3 quarters · filed 2023-02-21 | $33.82M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$646.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.69M derived: sum of 2 quarters · filed 2021-11-10 | $561.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $2.33M 10-Q · filed 2021-08-13 | $1.21M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |